At a recent lunch symposium during the 14th Annual Scientific Meeting of the Malaysian Society of Hypertension, Dr Chow Yok Wai spoke on the importance of patient adherence in the management of hypertension, highlighting the role of combination therapy in improving treatment outcomes.
At the 17th Malaysian Society of Rheumatology/Singapore Society of Rheumatology Workshop, Associate Professor Susanna Proudman, a senior consultant in rheumatology from Australia, shared with the audience on the diagnosis and management of pulmonary arterial hypertension (PAH), with a focus on systemic sclerosis (SSc)-related PAH.
At the recent launch of an exclusive guidebook on vasodilating β-blockers for the treatment of hypertension and chronic heart failure (HF), Professor Athanasios J. Manolis delivered a lecture on why nebivolol is different from the other agents in its class.
During the 8th Diabetes Complications Conference & Grand Rounds 2016, Dr Azani Mohamed Daud talked about the guidelines on the use of ACEIs and ARBs in hypertension, and highlighted their clinical efficacies for hypertension treatment.
Prof. Abdul Rashid, Prof. Martin Strauss, Prof. Alistair Hall, 20161212084416
Hypertension is a leading cause of mortality globally and is of particular concern in the Asia Pacific region where there are more deaths due to poor blood pressure (BP) control than in any other region in the world. At a recent Servier-sponsored satellite symposium held during the ASEAN Federation of Cardiology Congress in Yangon, Myanmar, Professor Abdul Rashid, An Nur Specialist Hospital, Selangor, Malaysia, discussed the challenges associated with managing hypertension in the region. In addition, Professor Martin Strauss, North York General Hospital, Toronto, Canada and Professor Alistair Hall, Leeds General Infirmary, UK, discussed the different effects of angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) on cardiovascular (CV) outcomes, highlighting the additional protection against myocardial infarction (MI) offered by ACE inhibitors such as perindopril.
Preventing hypertension, diabetes, and obesity, which are the major risk factors for heart failure (HF), by ages 45 and 55 years may lower risks of incident HF and prolong HF-free survival, suggests data from the Cardiovascular Disease Lifetime Risk Pooling Project.
The addition of evolocumab to statin therapy in individuals with angiographic coronary disease appeared to encourage coronary atherosclerosis regression, as demonstrated in the GLAGOV* trial presented at the Scientific Sessions of the American Heart Association (AHA 2016) held in New Orleans, Louisiana, US.
During the Ranexa® (ranolazine, A. Menarini) official launch symposium, renowned speaker Professor John Camm spoke on how ranolazine, a novel anti-anginal agent, could play a role in managing chronic stable angina (CSA). The session was followed by a lecture by Dr David Quek, who discussed the value of optimal medical therapy (OMT) in the management of CSA.
Blood pressure lowering medications and statins do not prevent cognitive and functional decline in elderly patients, according to results of the HOPE-3 trial* presented at the Scientific Sessions of the American Heart Association (AHA 2016) held recently in New Orleans, Louisiana, US.
Intravenous vasodilator therapy confers survival benefits and superior diuretic response in patients with acute heart failure (AHF), provided that systolic (SBP) reduction is <25 percent, according to a posthoc analysis.
Early detection of masked hypertension is essential, since young apparently healthy adults already show an increased left ventricular mass index, which indicates higher risk for future cardiovascular disease, according to a recent study.
In patients with uncontrolled blood pressure and severe hypertension, microvascular dysfunction is more pronounced and serum C-reactive protein (CRP) and endothelin levels are elevated, a recent study has found.